Research programme: G-protein coupled receptor modulators - Regeneron
Latest Information Update: 28 Dec 2025
At a glance
- Originator Regeneron Pharmaceuticals
- Class Single-domain antibodies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for research development in Unspecified in Belgium (Parenteral)
- 28 Dec 2025 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union